Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and...

cafead

Administrator
Staff member
  • cafead   Sep 01, 2022 at 10:32: AM
via Study met primary safety and secondary immunogenicity endpoints
Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects

article source